Senzime to conduct studies at Mayo Clinic, US
Uppsala, November 1, 2016. Senzime (publ) is initiating a series of clinical studies to be performed at Mayo Clinic, USA. The studies are intended to evaluate Senzime’s patient neuromonitoring system called TetraGraph, used during anesthesia. Data about the monitor’s ease of clinical use, form factor, design, and ease of set-up will be collected. The clinical validation studies at Mayo Clinic are intended to compare its usability to that of the now-discontinued former market leading monitoring system. Results are scheduled for presentation as early as December 2016.
Every year over 70 million surgical patients undergo general anesthesia combined with muscle relaxant drugs. Without objective neuromuscular monitoring to guide administration of relaxant drugs and determine appropriate timing to allow patients to breathe independently, about 30 percent of patients suffer postoperative complications. The TetraGraph is Senzime’s unique objective patient monitoring system that enables the clinician to administer the correct dose of muscle relaxant drugs, to time the administration of neuromuscular reversal agents, and to determine when the patient is able to breathe spontaneously without the need of mechanical ventilation. The use of objective neuromuscular monitors decreases postoperative patient complications such as low oxygen saturation, muscle weakness, pulmonary aspiration and postoperative pneumonia, hospital length of stay, and can lead to better care experience while reducing costs.
"The trend to require objective neuromuscular monitoring in patients who receive muscle relaxant drugs is increasing, and intraoperative monitoring has already become a standard of practice in several countries. Studies at Mayo Clinic will begin in November and we confidently look forward to the first results to be available in December 2016, "says Senzime’s CEO, Lena Söderström.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com